DOCSLIB.ORG

Fluoroquinolones in the Management of Acute Lower Respiratory Infection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluoroquinolones in the Management of Acute Lower Respiratory Infection Thorax 2000;55:83–85 83 Occasional review Thorax: first published as 10.1136/thorax.55.1.83 on 1 January 2000. Downloaded from The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults Peter J Moss, Roger G Finch Lower respiratory tract infections (LRTI) are ing for up to 40% of isolates in Spain19 and 33% the leading infectious cause of death in most in the United States.20 In England and Wales developed countries; community acquired the prevalence is lower; in the first quarter of pneumonia (CAP) and acute exacerbations of 1999 6.5% of blood/cerebrospinal fluid isolates chronic bronchitis (AECB) are responsible for were reported to the Public Health Laboratory the bulk of the adult morbidity. Until recently Service as showing intermediate sensitivity or quinolone antibiotics were not recommended resistance (D Livermore, personal communi- for the routine treatment of these infections.1–3 cation). Pneumococcal resistance to penicillin Neither ciprofloxacin nor ofloxacin have ad- is not specifically linked to quinolone resist- equate activity against Streptococcus pneumoniae ance and, in general, penicillin resistant in vitro, and life threatening invasive pneumo- pneumococci are sensitive to the newer coccal disease has been reported in patients fluoroquinolones.11 21 treated for respiratory tract infections with Resistance to ciprofloxacin develops rela- these drugs.4–6 The development of new fluoro- tively easily in both S pneumoniae and H influ- quinolone agents with increased activity enzae, requiring only a single mutation in the against Gram positive organisms, combined parC gene.22 23 Other quinolones such as with concerns about increasing microbial sparfloxacin and clinafloxacin require two resistance to â-lactam agents, has prompted a mutations in the parC and gyrA genes.11 23 re-evaluation of the use of quinolones in LRTI. Despite this, the prevalence of S pneumoniae Sparfloxacin and levofloxacin are now ap- with decreased quinolone sensitivity has in- http://thorax.bmj.com/ proved for the treatment of community ac- creased in parallel with increased prescription quired LRTIs in the UK (grepafloxin, which of these drugs,24 and pneumococci with was also approved for this indication, has decreased in vitro grepafloxacin sensitivity have recently been withdrawn from the market). It is been isolated from patients following treatment important to define the role of these drugs in with this agent.25 EZux resistance has been the treatment of CAP and AECB. recognised among S pneumoniae; some qui- The most common cause of CAP worldwide nolones appear to be more susceptible to this 11 26 27 is S pneumoniae which accounts for 60–75% of than others. In the case of H influenzae, on September 23, 2021 by guest. Protected copyright. pathogens isolated.7–9 Other less common some isolates from patients with LRTI have causes include Mycoplasma pneumoniae and developed decreased susceptibility to cipro- Legionella pneumophila. Any agent used for the floxacin; such isolates remain fully sensitive to empirical treatment of CAP must cover S clinafloxacin, trovafloxacin, and gatifloxacin pneumoniae, and preferably these other organ- but not to moxifloxacin, sparfloxacin, or isms as well, especially in severe disease. In grepafloxacin.11 AECB the role of bacterial pathogens is less The pharmacokinetic properties of the new clearly defined; Haemophilus influenzae, S pneu- quinolone agents support their use in LRTI. moniae, and Moraxella catarrhalis are most The drugs are extensively distributed, achiev- frequently associated. Several of the newer qui- ing high concentrations in lung tissues and 28 nolones have MIC90 values for S pneumoniae secretions. Those which are available in both that are significantly lower than those reported oral and intravenous formulations, such as Division of Infectious for ofloxacin and ciprofloxacin, which suggests levofloxacin and moxifloxacin, have good abso- Diseases and that they should be eVective in clinical use. lute bioavailability, allowing early and simple Microbiology, School Clinafloxacin, sitafloxacin, and gemifloxacin change from intravenous to oral treatment. of Clinical Laboratory have the lowest MIC90 values in vitro, followed Most have relatively long terminal elimination Sciences, University of by trovafloxacin, moxifloxacin, gatifloxacin, half lives and can be administered once daily. Nottingham, Nottingham City grepafloxacin, sparfloxacin, and levo- There are few published clinical trials 10–14 Hospital, Nottingham floxacin. All have excellent in vitro activity assessing the eYcacy of fluoroquinolones in NG5 1PB, UK against the other significant bacterial causes of CAP. Three studies have shown intravenous P J Moss CAP and AECB.15–18 and/or oral levofloxacin to be as good as or R G Finch Pneumococcal resistance to â-lactams is an better than comparative treatments 29 30 29 Correspondence to: increasing problem in many parts of the world, (ceftriaxone, oral cefuroxime, amoxycillin/ Professor R G Finch with penicillin resistant pneumococci account- clavulanic acid31) in terms of clinical and 84 Moss, Finch bacteriological cure. Sparfloxacin has been British guidelines are awaited. The antimicro- compared with erythromycin,32 bial spectrum and pharmacokinetic properties Thorax: first published as 10.1136/thorax.55.1.83 on 1 January 2000. Downloaded from roxithromycin,33 cefaclor,34 amoxycillin,35 of these agents suggest that they are likely to be amoxycillin/clavulanic acid,32 and an eVective treatment for respiratory infections amoxycillin/ofloxacin,36 again showing equival- due to penicillin resistant pneumococci and ent clinical and microbiological success rates. other organisms. However, clinical data are Single studies have shown grepafloxacin to be limited, particularly in severe and invasive dis- as eVective as, and trovafloxacin significantly ease. Potential compliance benefits due to once better than, amoxycillin (by clinical cure rate in daily dosing must be weighed against increased evaluable patients) for the treatment of drug cost; there is little practical evidence to CAP.37 38 Most patients entered into these support the suggestion (based on cost analysis comparative trials had mild or moderate rather models48) that quinolones may decrease the than severe pneumonia, based on accepted cost of treating CAP by reducing the need for clinical and laboratory indicators. Few have hospital admission. had bacteraemic pneumococcal pneumonia, a The prevalence of clinically significant pneu- more rigorous test of antimicrobial activity in mococcal resistance to penicillin in the UK is terms of disease severity, and only a very small currently low, although it is rising. Beta-lactam number of patients were infected with penicil- antibiotics alone or in combination with a lin resistant pneumococci. In most studies the macrolide remain adequate empirical treat- analysis was not performed on an intention-to- ment for most cases of CAP. There is no com- treat basis. Comparative clinical data on other pelling evidence for fluoroquinolones to be- new quinolones are limited and generally come the standard first line treatment for CAP. unpublished. Although there is a need for a safe and effective Levofloxacin, sparfloxacin, and grepa- parenteral/oral agent for treating severe CAP in floxacin have been shown to be as eVective hospital, it is not yet clear if any of the currently clinically as comparative oral treatment (ce- available quinolones can fill this role. Antibiot- furoxime axetil or amoxycillin/clavulanate) for ics are usually not indicated in AECB49 and treating AECB.39–41 However, most acute exac- there is little evidence to suggest that quinolo- erbations of bronchitis are not due primarily to nes oVer benefit over other antimicrobial treat- bacterial infection, and diYculty in defining ments, although they may be used as second the role of antibiotics in treatment has made line drugs in a few cases where an antibiotic is comparative trials problematic. appropriate. Safety is paramount if quinolones are to gain wider use in the community as well as in hospi- 1 American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumo- tal. Most adverse events reported are common nia: diagnosis, assessment of severity and initial antimicro- to the class, but the frequency and severity bial therapy. Am Rev Respir Dis 1993;148:1418–26. 2 Mandell LA, Niederman MS. Antimicrobial treatment of varies from drug to drug. Recent reports of community acquired pneumonia in adults: a conference http://thorax.bmj.com/ hepatotoxicity have led to the product licence report. Can J Infect Dis 1993;4:25–8. 3 British Thoracic Society. Guidelines for the management of for trovafloxacin being suspended in the UK community-acquired pneumonia in adults admitted to 42 and restricted in the USA. Nausea and other hospital. Br J Hosp Med 1993;49:346–50. minor gastrointestinal problems are common 4 Frieden TR, Mangi RJ. Inappropriate use of oral cipro- floxacin. JAMA 1990;264:1438–40. with all quinolones, as are mild CNS eVects 5 Lee BL, Kimbrough RC, Jones SR, et al. Infectious compli- such as dizziness, headache, and light headed- cations with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520–1. ness. These eVects may be more common with 6 Korner RJ, Reeves DS, MacGowan AP. Dangers of oral grepafloxacin.43 Photosensitivity is more com- fluoroquinolone treatment in community acquired upper respiratory tract infections. BMJ 1994;308:191–2. mon and more severe with 8-halogenated
Load more

Recommended publications
  • Antibiotic Resistance in the European Union Associated with Therapeutic Use of Veterinary Medicines
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/342/99-Final Antibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines Report and Qualitative Risk Assessment by the Committee for Veterinary Medicinal Products 14 July 1999 Public 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8447 E_Mail: [email protected] http://www.eudra.org/emea.html ãEMEA 1999 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS Page 1. INTRODUCTION 1 1.1 DEFINITION OF ANTIBIOTICS 1 1.1.1 Natural antibiotics 1 1.1.2 Semi-synthetic antibiotics 1 1.1.3 Synthetic antibiotics 1 1.1.4 Mechanisms of Action 1 1.2 BACKGROUND AND HISTORY 3 1.2.1 Recent developments 3 1.2.2 Authorisation of Antibiotics in the EU 4 1.3 ANTIBIOTIC RESISTANCE 6 1.3.1 Microbiological resistance 6 1.3.2 Clinical resistance 6 1.3.3 Resistance distribution in bacterial populations 6 1.4 GENETICS OF RESISTANCE 7 1.4.1 Chromosomal resistance 8 1.4.2 Transferable resistance 8 1.4.2.1 Plasmids 8 1.4.2.2 Transposons 9 1.4.2.3 Integrons and gene cassettes 9 1.4.3 Mechanisms for inter-bacterial transfer of resistance 10 1.5 METHODS OF DETERMINATION OF RESISTANCE 11 1.5.1 Agar/Broth Dilution Methods 11 1.5.2 Interpretative criteria (breakpoints) 11 1.5.3 Agar Diffusion Method 11 1.5.4 Other Tests 12 1.5.5 Molecular techniques 12 1.6 MULTIPLE-DRUG RESISTANCE
    [Show full text]
  • Zagam® (Sparfloxacin) Tablets Contain Sparfloxacin, a Synthetic Broad-Spectrum Antimicrobial Agent for Oral Administration
    Zagam Rx only DESCRIPTION: Zagam® (sparfloxacin) tablets contain sparfloxacin, a synthetic broad-spectrum antimicrobial agent for oral administration. Sparfloxacin, an aminodifluoroquinolone, is 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1- piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid. Its empirical formula is C19H22F2N4O3 and it has the following chemical structure: Sparfloxacin has a molecular weight of 392.41. It occurs as a yellow crystalline powder. It is sparingly soluble in glacial acetic acid or chloroform, very slightly soluble in ethanol (95%), and practically insoluble in water and ether. It dissolves in dilute acetic acid or 0.1 N sodium hydroxide. Zagam is available as a 200-mg round, white film-coated tablet. Each 200-mg tablet contains the following inactive ingredients: microcrystalline cellulose NF, corn 1 Zagam starch NF, L-hydroxypropylcellulose NF, magnesium stearate NF, and colloidal silicone dioxide NF. The film coating contains: methylhydroxypropylcellulose USP, polyethylene glycol 6000, and titanium dioxide USP. CLINICAL PHARMACOLOGY: Absorption: Sparfloxacin is well absorbed following oral administration with an absolute oral bioavailability of 92%. The mean maximum plasma sparfloxacin concentration following a single 400-mg oral dose was approximately 1.3 (±0.2) µg/mL. The area under the curve (mean AUC0→∞) following a single 400-mg oral dose was approximately 34 (±6.8) µg•hr/mL. Steady-state plasma concentration was achieved on the first day by giving a loading dose that was double the daily dose. Mean (± SD) pharmacokinetic parameters observed for the 24-hour dosing interval with the recommended dosing regimen are shown below: Dosing Regimen Peak Trough AUC0→24 (mg/day) Cmax C24 (µg/mL) hr.
    [Show full text]
  • Screening of Pharmaceuticals in San Francisco Bay Wastewater
    Screening of Pharmaceuticals in San Francisco Bay Wastewater Prepared by Diana Lin Rebecca Sutton Jennifer Sun John Ross San Francisco Estuary Institute CONTRIBUTION NO. 910 / October 2018 Pharmaceuticals in Wastewater Technical Report Executive Summary Previous studies have shown that pharmaceuticals are widely detected in San Francisco Bay, and some compounds occasionally approach levels of concern for wildlife. In 2016 and 2017, seven wastewater treatment facilities located throughout the Bay Area voluntarily collected wastewater samples and funded analyses for 104 pharmaceutical compounds. This dataset represents the most comprehensive analysis of pharmaceuticals in wastewater to date in this region. On behalf of the Regional Monitoring Program for Water Quality in San Francisco Bay (RMP), the complete dataset was reviewed utilizing RMP quality assurance methods. An analysis of influent and effluent information is summarized in this report, and is intended to inform future monitoring recommendations for the Bay. Influent and effluent concentration ranges measured were generally within the same order of magnitude as other US studies, with a few exceptions for effluent. Effluent concentrations were generally significantly lower than influent concentrations, though estimated removal efficiency varied by pharmaceutical, and in some cases, by treatment type. These removal efficiencies were generally consistent with those reported in other studies in the US. Pharmaceuticals detected at the highest concentrations and with the highest frequencies in effluent were commonly used drugs, including treatments for diabetes and high blood pressure, antibiotics, diuretics, and anticonvulsants. For pharmaceuticals detected in discharged effluent, screening exercises were conducted to determine which might be appropriate candidates for further examination and potential monitoring in the Bay.
    [Show full text]
  • FLUOROQUINOLONES: from Structure to Activity and Toxicity
    FLUOROQUINOLONES: from structure to activity and toxicity F. Van Bambeke, Pharm. D. & P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université Catholique de Louvain, Brussels, Belgium SBIMC / BVIKM www.sbimc.org - www.bvikm.org www.md.ucl.ac.be/facm www.isap.org soon... Mechanism of action of fluoroquinolones: the basics... PORIN DNA Topo DNA gyrase isomerase Gram (-) Gram (+) 2 key enzymes in DNA replication: DNA gyrase topoisomerase IV bacterial DNA is supercoiled Ternary complex DNA - enzyme - fluoroquinolone DNA GYRASE catalytic subunits COVALENTLY CLOSED CIRCULAR DNA FLUOROQUINOLONES: DNA GYRASE ATP binding subunits 4 stacked molecules (Shen, in Quinolone Antimicrobial Agents, 1993) Resistance to fluoroquinolones: the basics decreased efflux pump permeability DNA mutation of DNA gyrase Topo isomerase the enzymes Gram (-) Gram (+) Fluoroquinolones are the first entirely man-made antibiotics: do we understand our molecule ? R5 O R COOH 6 R7 X8 N R1 Don’t panic, we will travel together…. Chemistry and Activity This is where all begins... The pharmacophore common to all fluoroquinolones BINDING TO DNA R5 O O R C 6 - BINDING TO O BINDING TO THE ENZYME THE ENZYME R7 X8 N R1 AUTO-ASSEMBLING DOMAIN (for stacking) From chloroquine to nalidixic acid... nalidixic acid N CH3 O O HN CH 3 C - O chloroquine CH N N Cl N 3 C2H5 1939 O O C O- 1962 Cl N 1958 C2H5 7-chloroquinoline (synthesis intermediate found to display antibacterial activity) Nalidixic acid * a • typical chemical features of O O fluoroquinolones (a, b, c) BUT a naphthridone C - O- b (N at position 8: ) H C N N 3 • limited usefulness as drug C H 2 5 • narrow antibacterial spectrum c (Enterobacteriaceae only) • short half-life (1.5h) • high protein binding (90%) * Belg.
    [Show full text]
  • Ranking of Major Classes of Antibiotics for Activity
    RANKING OF MAJOR CLASSES OF ANTIBIOTICS FOR ACTIVITY AGAINST STATIONARY PHASE GRAM-NEGATIVE BACTERIA PSEUDOMONAS AERUGINOSA AND CARBAPENEMASE-PRODUCING KLEBSIELLA PNEUMONIAE AND IDENTIFICATION OF DRUG COMBINATIONS THAT ERADICATE THEIR PERSISTENT INFECTIONS by Yuting Yuan A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Science Baltimore, Maryland April, 2019 ABSTRACT From the earliest identification of different bacterial phenotypic states, researchers found under antibiotic exposure, there are some bacteria that can keep dormant in a non-growing state as persister cells. These dormant persister bacteria can revert back to the growing population when the antibiotics are removed. The formation of bacterial persister cells establishes phenotypic heterogeneity within a bacterial population and is important for increasing the chances of successfully adapting to environmental change. Persister cells were first discovered in Staphylococcus sp. in 1944 when penicillin failed to kill a small subpopulation of bacterial cells. Persisters exhibit temporary antibiotic-tolerant phenotype and the underlying mechanisms involved in the induction and regulation of persister cells formation have been investigated by the previous lab members regarding mechanisms of persistence in Borrelia burgdorferi and with Yin-Yang Model to illustrate persistent infection. This investigation focuses on the optimal treatment for persistent infection. Because current treatments for such chronic persistent infections are not effective and antibiotic phenotypic resistance is a significant issue. The discovery of antibiotics and their widespread use represent a significant milestone in human history since the 20th century. However, their efficacy has declined at an alarming rate due to the spread of antibiotic resistance, and persistence and the evidence is accumulating that persister cells can contribute to the emergence of antibiotic resistance.
    [Show full text]
  • Molecular Docking Studies of Some Novel Fluoroquinolone Derivatives
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 30 January 2019 doi:10.20944/preprints201901.0307.v1 1 Article 2 Molecular Docking Studies of Some Novel 3 Fluoroquinolone Derivatives 4 Lucia Pintilie* and Amalia Stefaniu 5 1 National Institute for Chemical‐Pharmaceutical Research and Development, 112 Vitan Av., 74373, 6 Bucharest, Romania, e‐mails: [email protected] (L.P), [email protected] (A.S) 7 * Correspondence: [email protected]; Tel.: +40 21 322 29 17 8 9 10 Abstract: An important parameter in the development of a new drug is the drugʹs affinity to the 11 identified target (protein/enzyme). Predicting the ligand binding to the protein assembly by 12 molecular simulations would allow the synthesis to be restricted to the most promising drug 13 candidates. A restricted hybrid HF‐DFT calculation was performed in order to obtain the most stable 14 conformer of studied ligands and a series of DFT calculations using the B3LYP levels with 6‐31G* 15 basis set has been conducted on their optimized structures. The docking studies of the quinolone 16 compounds have been carried out with CLC Drug Discovery Workbench software to identify and 17 visualize the ligand‐receptor interaction mode. 18 Keywords: molecular docking; fluoroquinolones; antimicrobial activity 19 20 1. Introduction 21 Infectious diseases are the second important cause of death global [1]. Treatment of infectious 22 diseases becomes more difficult when common pathogens, such as Staphylococcus aureus and 23 Mycobacterium tuberculosis develop drug resistance to drugs that were considered at one time, 24 effective. Antibiotic drugs are a special class of therapeutic agents whose misuse have affected not 25 only the individual patient, they have affected also the entire community.
    [Show full text]
  • De Novo Design of Type II Topoisomerase Inhibitors As Potential Antimicrobial Agents Targeting a Novel Binding Region Kyle M. Or
    De Novo Design of Type II Topoisomerase Inhibitors as Potential Antimicrobial Agents Targeting a Novel Binding Region Kyle M. Orritta, Juliette F. Newella, Thomas Germeb, Lauren R. Abbottb,1, Holly L. Jacksona, Benjamin K. L. Burya, Anthony Maxwellb*, Martin J. McPhilliea*, Colin W. G. Fishwicka* a School of Chemistry, University of Leeds, Leeds, LS2 9JT, United Kingdom b Dept. Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, United Kingdom 1 Dept. of Molecular and Cell Biology, University of Leicester, Leicester, LE1 7RH, United Kingdom *Corresponding authors: [email protected], [email protected], [email protected] Abstract By 2050 it is predicted that antimicrobial resistance will be responsible for 10 million global deaths annually, costing the world economy $100 trillion. Clearly, strategies to address this problem are required as bacterial evolution is rendering our current antibiotics ineffective. The discovery of an allosteric binding site on the established antibacterial target DNA gyrase offers a new medicinal chemistry strategy, as this site is distinct from the fluoroquinolone-DNA site binding site. Using in silico molecular design methods, we have designed and synthesised a novel series of biphenyl-based inhibitors inspired by the published thiophene allosteric inhibitor. This series was evaluated in vitro against E. coli DNA gyrase, exhibiting IC50 values in the low micromolar range. The structure-activity relationship reported herein suggests insights to further exploit this allosteric site, offering a pathway to overcome fluoroquinolone resistance. Keywords DNA gyrase, antimicrobial resistance, structure-based molecular design, de novo design, allosteric inhibitors The evolution of antibiotic resistance poses an enormous threat to human health.
    [Show full text]
  • TROVAN® Tablets(Trovafloxacin Mesylate)
    TROVAN- trovafloxacin mesylate tablet, film coated TROVAN- trovafloxacin mesylate injection, solution, concentrate Roerig ---------- TROVAN® Tablets (trovafloxacin mesylate) TROVAN® I.V. (alatrofloxacin mesylate injection) For Intravenous Infusion TROVAN® HAS BEEN ASSOCIATED WITH SERIOUS LIVER INJURY LEADING TO LIVER TRANSPLANTATION AND/OR DEATH. TROVAN-ASSOCIATED LIVER INJURY HAS BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS LIVER INJURY. LIVER INJURY HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE- EXPOSURE. TROVAN SHOULD BE RESERVED FOR USE IN PATIENTS WITH SERIOUS, LIFE- OR LIMB-THREATENING INFECTIONS WHO RECEIVE THEIR INITIAL THERAPY IN AN IN-PATIENT HEALTH CARE FACILITY (I.E., HOSPITAL OR LONG-TERM NURSING CARE FACILITY). TROVAN SHOULD NOT BE USED WHEN SAFER, ALTERNATIVE ANTIMICROBIAL THERAPY WILL BE EFFECTIVE. (SEE WARNINGS.) TROVAN is available as TROVAN Tablets (trovafloxacin mesylate) for oral administration and as TROVAN I.V. (alatrofloxacin mesylate injection), a prodrug of trovafloxacin, for intravenous administration. DESCRIPTION TROVAN Tablets TROVAN Tablets contain trovafloxacin mesylate, a synthetic broad-spectrum antibacterial agent for oral administration. Chemically, trovafloxacin mesylate, a fluoronaphthyridone related to the fluoroquinolone antibacterials, is (1α, 5α, 6α)-7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4- difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate. Trovafloxacin mesylate differs from other quinolone derivatives by having a 1,8-naphthyridine nucleus. The chemical structure is: Its empirical formula is C20H15F3N4O3•CH3SO3H and its molecular weight is 512.46. Trovafloxacin mesylate is a white to off-white powder.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Grepafloxacin Susceptibility Against Penicillin Resistant
    Invasive Streptococcus pneumoniae in Canada 2011: Study of Antimicrobial Resistance and Serotypes Alyssa Golden Department of Clinical Microbiology, Health Sciences Centre, and Faculty of Medicine, University of Manitoba Correspondence: Alyssa Golden c/o Dr. G.G. Zhanel Department of Clinical Microbiology Health Sciences Centre MS673 - 820 Sherbrook Street Winnipeg, Manitoba R3A 1R9 CANADA Phone: (204) 787-4902 Fax: (204) 787-4699 email: [email protected] Introduction Infections caused by Streptococcus pneumoniae are of critical concern, as respiratory and invasive isolates are commonly resistant to many drug classes, including penicillins. They are also frequently multi-drug resistant (simultaneous resistance to e3 structurally unrelated classes). A conjugate vaccine Prevnar® (PCV-7: 4, 6B, 9V, 14, 18C, 19F, 23F) has been used in Canada to great effect, reducing the number of invasive S. pneumoniae infections observed in children. However, S. pneumoniae serotypes that are not related to the vaccine are rising in Canada. For this reason, a new vaccine, PCV- 13 (PCV-7 + 1, 3, 5, 6A, 7F and 19A), was recently released in Canada to combat the rise of non-vaccine serotypes, especially 19A. This vaccination allows for broader coverage of S. pneumoniae serotypes. The purpose of my summer research project was to study invasive S. pneumoniae in Canada (2011) and assess their serotypes and antimicrobial resistance. Hypotheses PCV-13 will provide greater coverage of S. pneumoniae isolates than PCV-7. With the continued use of these conjugated vaccines, a greater proportion of non- vaccine serotypes will circulate in Canada. These serotypes will also be antimicrobial resistant. Methods Isolates tested were obtained from all geographic regions of Canada during the 2011 year.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides
    Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides a, b,c Luke F. Chen, MBBS (Hons), MPH, CIC, FRACP *, Donald Kaye, MD KEYWORDS Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin The polymyxins, rifamycins, and the aminoglycosides may be considered special use antibacterial agents. They are all old agents and are rarely considered the drugs of choice for common bacterial infections. The polymyxins are increasingly important because of the continued emergence of multidrug resistant (MDR) gram-negative organisms, such as strains of Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae that are susceptible to few remaining drugs. Rifampin is only considered in the context of nonmycobacterial infections where its role is limited and sometimes controversial. Rifaximin is a new enteric rifamycin that is increasingly used for gastrointestinal infections such as trav- eler’s diarrhea and Clostridium difficile infections (CDIs). This article will also review the current role of aminoglycosides in nonmycobacterial systemic infections, with an emphasis on the use of single daily administration. POLYMYXINS The polymyxins were discovered in 1947. Although there are five known polymyxin molecules, sequentially named polymyxin A through polymyxin E, only two polymyxins are available for therapeutic use: polymyxin B and polymyxin E (colistin) (Table 1). Both polymyxin B and polymyxin E are large cyclic cationic polypeptide detergents A version of this article appeared in the 23:4 issue of the Infectious Disease Clinics of North America. a Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA b Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA c 1535 Sweet Briar Road, Gladwyne, PA 19035, USA * Corresponding author.
    [Show full text]